|Bid||46.26 x 1200|
|Ask||46.60 x 1100|
|Day's Range||45.49 - 46.83|
|52 Week Range||11.27 - 46.84|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.38|
NEW YORK , Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Roku (NASDAQ: ROKU ) shares were up 5.5% to ...
Ra Pharma stock rocketed by more than 100% Thursday after Belgium biotech company UCB agreed to acquire it for $2.1 billion. Ra Pharma is working on a treatment for a muscular condition.
NEW YORK, Oct. 10, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ra Pharmaceuticals, Inc. (“Ra.
The Cambridge biotech, which is in late-stage trials of a drug to treat a rare muscle disease, has been acquired by Belgium-based UCB for $2.1 billion, immediately doubling the market value of the Cambridge firm.
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders ...
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc. ("RARX" or the ...
WILMINGTON, DE / ACCESSWIRE / October 10, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX )? Did you purchase any of your shares prior to October 10, 2019? ...
NEW YORK, Oct. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) to UCB S.A. (“UCB”).
Ra Pharm is a clinical-stage biopharma engaged in the development of therapies for serious diseases caused by excessive activation of the complement system, a critical component of the innate immune system. UCB is paying $48 per share in cash for the company, or $2.5 billion. Net of Ra Pharma's cash, the transaction is valued at $2.1 billion.
SAN DIEGO , Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
Belgian biopharma company UCB has agreed to acquire Ra Pharmaceuticals Inc. in a cash deal valued at about $2.5 billion, the companies said Thursday. Ra Pharma shareholders will receive $48 per share, equal to a 93% premium over the 30-day volume weighted closing stock price of Ra Pharma prior to signing. The deal has been approved by the boards of both companies and is expected to close by the end of the first quarter of 2020. Cambridge, Mass-based Ra Pharma is a clinical-stage biopharma company focused on development treatments for serious diseases caused by the immune system. "The company's ExtremeDiversity(TM) platform enables the production of synthetic macrocyclic peptides combining the diversity and specificity of antibodies with the pharmacological properties of small molecules," said the statement. The company's phase 3 product candidate zilucoplan had positive results in a phase 2 trial as a treatment for myasthenia gravis, of gMG, a chronic auto-immune condition in which auto-antibodies attack specific proteins in the neuro-muscular junction. That causes muscle weakness and fatigue and affects almost 200,000 patients in the U.S., EU and Japan, said the statement. Ra Pharma shares rose 107% in premarket trade on the news, and are up 25% in 2019 through Wednesday, while the S&P 500 has gained 16%.
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, ...
Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology. "Ra Pharma is an excellent strategic fit addressing multiple areas of UCB's patient value growth strategy," UCB's Chief Executive Officer Jean-Christophe Tellier said in a joint statement. The acquisition of the clinical-stage biopharmaceutical company, which was founded in 2008, is expected to contribute to UCB's core earning per share and increase its revenue and net profit from 2024 onwards.
Ra Pharmaceuticals, Inc. (RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). “In a Phase 2 clinical trial, zilucoplan achieved rapid, clinically meaningful, and statistically significant reductions in primary and key secondary efficacy endpoints, with a durable treatment effect that was sustained at 24 weeks for patients enrolled in the long-term extension study,” said James F. Howard, M.D., Distinguished Professor of Neuromuscular Disease, Department of Neurology, University of North Carolina School of Medicine.
Ra Pharmaceuticals, Inc. (RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M. Healey & AMG Center for ALS at Mass General. The Healey Center has agreed to provide funding for the execution of the platform trial to support its goal of accelerating the development of effective treatments for patients with ALS. “The Healey Center brought together top leaders from around the world to dramatically re-think how we design ALS trials and create a groundbreaking platform trial program,” says Merit Cudkowicz, M.D., M.Sc., director of the Sean M. Healey & AMG Center for ALS at Mass General.
Ra Pharmaceuticals, Inc. (RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis (gMG) and other rare, tissue-based complement-mediated diseases. “gMG is a chronic and debilitating neuromuscular disease that affects more than 60,000 patients in the U.S. who have limited treatment options,” said Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma.